Oncolytic Viral Vaccine Toxicology at CBI

Oncolytic viral vaccines represents a novel and exciting approach to the treatment of cancer. In 2015, the U.S. Food and Drug Administration approved the first oncolytic virus immunotherapy for the treatment of cancer - T-VEC for melanoma. There are now a number of exciting new products in development. CBI has conducted a number of toxicology programs with oncolytic viral vaccines for our clients.

ALL CBI STUDIES SUCCESSFUL!

CBI specializes in customizing, designing and implementing GLP toxicology studies for regulatory submissions as well as research and nonGLP studies with oncolytic vaccine products:

- Immune-incompetent or competent mice, both tumor bearing and non-tumor bearing
- Unique and specialized assessments
- Murine cardiac troponins
- Immunohistochemistry
- Cytokines and mediators
- qPCR, Print and ADA bioassays
- Customized and special assays

- CUSTOM UPON REQUEST -

NEED TO CONDUCT A STUDY?

Click here and check out our website. www.compbio.com

Comparative Biosciences Inc.
A TRANSLATIONAL APPROACH TO BIOMEDICAL SERVICES

786 Lucerne Drive  .  Sunnyvale, CA 94085  .  Telephone 408-738-9260